Immuno Oncology (IO) Market Size Worth $92.71 Billion By 2029 | CAGR: 23.4%

The global immuno oncology (IO) market size is expected to reach USD 92.71 Billion by 2029 according to a new study by Polaris Market Research. The report “Immuno Oncology (IO) Market Share, Size, Trends, Industry Analysis Report By Treatment Approaches; By Novel Targets (IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, A2AR antagonist/CD73i); By Tumor Type; By Region, Segment Forecast, 2022 - 2029” gives a detailed insight into current market dynamics and provides analysis on future market growth.

In recent years, IO has made significant progress with government authorization for cytokines, vaccinations, tumor-directed monoclonal antibodies, and immune checkpoint blockers, among other I-O medicines. Increasing awareness regarding I-O advantages over conventional methods is expected to fuel the industry's growth.

IO therapies activate the immune system that helps to address a larger patient population rather than only cancer treatments which in turn will create novel opportunities for the industry growth over the forecast period.

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market/request-for-sample

North America dominated the global IO industry in 2021 and is expected to maintain its dominance over the forecast period due to a high number of cancer cases along with the well-established healthcare sector. However, Asia Pacific is expected to grow at the fastest pace during the forecast period due to government initiatives to improve the healthcare sector.

Some of the players operating in the global industry include AstraZeneca, Amgen, Inc., Bristol Myers Squibb, Eli Lilly and Company, Celgene Corporation, F. Hoffmann-La Roche AG, Incyte, GlaxoSmithKline Plc., Janssen Biotech, Inc., Merck, Pfizer, Novartis AG, Roche, Spectrum Pharmaceuticals Sanofi, and Takeda Pharmaceuticals.

Polaris Market Research has segmented the immuno oncology (IO) market report on the basis of treatment approaches, novel targets, tumor types, and region:

Immuno Oncology (IO), Treatment Approaches Outlook (Revenue - USD Billion, 2017-2029)

• Monoclonal Antibodies
• Therapeutic Vaccines
• Checkpoint Inhibitors
• Cytokines

Immuno Oncology (IO), Novel Targets Outlook (Revenue - USD Billion, 2017 - 2029)

• IDO1i
• LAG-3 CPI
• Oncolytic virus
• STING agonist
• TLR agonist
• HDACi
• TIL
• VEGFi
• MEKi
• TIGIT
• CPI
• GITR agonist
• TGF-b trap
• A2AR antagonist/CD73i

Immuno Oncology (IO), Tumor Type Outlook (Revenue - USD Billion, 2017 - 2029)

• Melanoma
• Non-Small Cell Lung Cancer
• Renal Cell Carcinoma
• Head & Neck Cancer
• Bladder Cancer
• Classical Hodgkin’s Lymphoma
• Merkel Cell Carcinoma
• Others

Immuno Oncology (IO), Regional Outlook (Revenue - USD Billion, 2017 - 2029)

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Austria
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Indonesia
  • Malaysia
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • Israel
  • Saudi Arabia
  • South Africa
  • UAE